FindTrial
Sign In

A Study on the Clinical Value of Dual-Phase 68Ga-FAPI-04 PET/CT and PET/MR in Tumors and Non-Tumor Lesions

A Study on the Clinical Value of Dual-Phase 68Ga-FAPI-04 PET/CT and PET/MR in Tumors and Non-Tumor Lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117535
Enrollment
Unknown
Registered
2026-01-26
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Gold Standard:Histopathological examination serves as the gold standard. Clinical and radiological follow-up results over a minimum period of three months serve as the reference standard.
Index test:Dual-phase68Ga-FAPI-04 PET/CT or PET/MR
SUVmax

Sponsors

chongqing university cancer hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years or older; 2. Patients with pathologically confirmed or clinically suspected tumors, or those who have undergone tumor treatment; 3. Patients who underwent conventional and regional delayed 68Ga-FAPI-04 PET/CT or PET/MR scans, specifically: conventional scanning approximately 1 hour after radiotracer injection, and regional delayed scanning approximately 2 hours after radiotracer injection.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients undergoing routine scanning only one hour after injection of 68Ga-FAPI-04.

Design outcomes

Primary

MeasureTime frame
SUVmax-early;accuracy;SUVmax-delayed;?SUVmax%;sensitivity;specificity;—

Countries

China

Contacts

Public ContactXiaoliang Chen

chongqing university cancer hospital

928862116@qq.com+86 23 65070529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026